Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) reported new 48-week KINECT 4 post-hoc data on INGREZZA (valbenazine) for tardive dyskinesia. About 94% of patients achieved either symptomatic remission or a ≥30% AIMS score reduction.

A separate Medicare claims study of 176,000+ TD patients found 90% had hepatic risk factors; INGREZZA is the only VMAT2 inhibitor with approved dosing in hepatic impairment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• 94% of INGREZZA-treated patients achieved remission or ≥30% AIMS reduction at 48 weeks
• Overall symptomatic remission rate of 59% (61/103) after 48 weeks of treatment
• Remission achieved in 63% of moderate and 54% of severe tardive dyskinesia patients
• Among non-remitters, 86% achieved ≥30% and 67% achieved ≥50% AIMS score reduction
• Medicare claims show 90% of 176,000+ TD patients have ≥1 hepatic risk factor and 44% have ≥3
• INGREZZA described as the only VMAT2 inhibitor with approved dosing for TD patients with hepatic impairment

Negative

• None.

News Market Reaction – NBIX

-0.15%

-0.15% News Effect

On the day this news was published, NBIX declined 0.15%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement adds detailed 48‑week KINECT 4 data showing 94% of patients on INGREZZA achieved s...

Analysis

This announcement adds detailed 48‑week KINECT 4 data showing 94% of patients on INGREZZA achieved symptomatic remission or clinically meaningful AIMS score reductions, plus a large Medicare analysis of hepatic risk factors in tardive dyskinesia. It builds on a series of recent NBIX updates around INGREZZA and TD. Investors may watch how future data readouts, real‑world outcomes, and safety considerations in hepatic impairment shape the therapy’s positioning within VMAT2 inhibitors.

Key Figures

Overall response rate: 94% of participants Symptomatic remission: 59% (61/103) of patients Remission in moderate TD: 63% (38/60) of patients +5 more

8 metrics

Overall response rate 94% of participants 48-week KINECT 4 post-hoc analysis (INGREZZA-treated TD patients)

Symptomatic remission 59% (61/103) of patients Previously presented 48-week KINECT 4 data, once-daily INGREZZA

Remission in moderate TD 63% (38/60) of patients KINECT 4 symptomatic remission, moderate tardive dyskinesia subgroup

Remission in severe TD 54% (23/43) of patients KINECT 4 symptomatic remission, severe tardive dyskinesia subgroup

Clinically meaningful response 86% (36/42) of non-remitters ≥30% AIMS total score reduction at Week 48

Deep response 67% (28/42) of non-remitters ≥50% AIMS total score reduction at Week 48

Claims analysis sample size More than 176,000 patients Retrospective Medicare claims, newly diagnosed TD

Hepatic risk prevalence 90% ≥1 risk factor; 44% ≥3 Medicare TD cohort hepatic risk factors

Historical Context

5 past events · Latest: Jun 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 08	INGREZZA TD data	Positive	-0.2%	New data on TD and developmental disability patients treated with INGREZZA.
Jun 03	Conference preview	Positive	+6.6%	Planned two-year CRENESSITY and VYKAT XR data presentations at ENDO 2026.
May 26	Investor conferences	Neutral	+0.1%	Participation in June investor conferences with executive fireside chats.
May 18	Real‑world TD data	Positive	-2.2%	Real‑world survey showing functional gains in mild TD patients on INGREZZA.
May 18	Soleno acquisition	Neutral	-0.8%	Completion of Soleno purchase, adding VYKAT XR for Prader‑Willi hyperphagia.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent NBIX news has often been clinically positive, but price reactions are mixed, with 3 divergences and 2 alignments over the last five events.

Recent Company History

Over the past few weeks, NBIX has repeatedly highlighted INGREZZA data in tardive dyskinesia, including real‑world and functional outcomes, alongside today’s new KINECT 4 response and hepatic‑risk analyses. The company also announced upcoming ENDO 2026 presentations for CRENESSITY and completed a $2.9 billion Soleno acquisition, adding VYKAT XR to its portfolio. Price reactions to these milestones have varied, with both positive and negative moves after largely constructive updates.

Regulatory & Risk Context

Short Interest: 7.3%

Short Interest

7.3% of float

0% 15% 30%+

low as of 2026-05-29 Days to cover: 4.96

Key Terms

tardive dyskinesia, Abnormal Involuntary Movement Scale, vesicular monoamine transporter 2, VMAT2, +4 more

8 terms

tardive dyskinesia medical

"adults with tardive dyskinesia (TD) treated with INGREZZA"

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

Abnormal Involuntary Movement Scale medical

"≥30% reduction from baseline in Abnormal Involuntary Movement Scale total score"

AIMS is a standardized clinical checklist doctors use to spot and rate involuntary movements—like facial grimacing, tongue or limb twitching—that can be caused by certain medications. For investors, AIMS scores matter because they are a practical safety measurement in drug trials and ongoing monitoring; high or worsening scores can lead to stronger warnings, tougher regulatory review, reduced marketability or costly label changes, much like a vehicle inspection report revealing serious faults.

vesicular monoamine transporter 2 medical

"only vesicular monoamine transporter 2 (VMAT2) inhibitor to demonstrate clinical remission"

Vesicular monoamine transporter 2 (VMAT2) is a protein in nerve cells that acts like a loading dock, moving signaling chemicals such as dopamine and serotonin into storage packets so they can be released at the right time. Investors watch VMAT2 because drugs or imaging tests that affect or measure it can be used to treat or diagnose neurological and psychiatric conditions, creating potential markets, clinical milestones, and regulatory events that affect company value.

VMAT2 medical

"INGREZZA is the only VMAT2 inhibitor with approved dosing in hepatic impairment"

VMAT2 is a protein that acts like a tiny pump in certain brain cells, moving chemical messengers such as dopamine into storage packets so they can be released when cells signal. Investors care because drugs or imaging tests that affect or measure VMAT2 can change how neurological and movement disorders are diagnosed and treated; successful therapies or validated diagnostic scans can alter clinical trial outcomes, regulatory decisions and market value in the healthcare sector.

hepatic impairment medical

"only VMAT2 inhibitor with approved dosing for patients with TD and coexisting hepatic impairment"

Hepatic impairment means the liver is not working normally, which changes how the body breaks down and clears medicines and other substances. For investors, this matters because weakened liver function can force dose changes, limit which patients can use a drug, or raise safety concerns—similar to a factory running slower and producing fewer usable products—affecting regulatory approval, market size, and sales forecasts.

hepatic risk factors medical

"claims analysis indicates high prevalence of hepatic risk factors among patients"

Hepatic risk factors are patient characteristics, medical conditions, medications, or environmental exposures that increase the likelihood of liver injury or reduced liver function. They matter to investors because products, clinical trials, and regulatory reviews tied to liver safety often face extra testing, slower approvals, higher development costs, narrower labels, or greater legal risk — like a ship needing stronger packaging and insurance when bad weather is likely.

Medicare claims analysis medical

"A separate retrospective Medicare claims analysis of more than 176,000 patients"

Medicare claims analysis is the examination of billing records and related data generated when Medicare pays for medical services, prescriptions, and procedures. It reveals patterns in who is receiving care, what treatments are being used, and how much is being spent—like reading a stack of receipts to see what customers actually buy. Investors use these insights to estimate market demand, product adoption, pricing trends and potential revenue or risk for healthcare companies.

Positron Emission Tomography medical

"Results from a Positron Emission Tomography Study in Healthy Male Adults"

A positron emission tomography (PET) scan is an imaging test that uses a tiny amount of radioactive tracer injected into the body to map how organs and tissues are functioning, similar to watching traffic flow on a city map rather than just seeing roads. Investors care because PET technology and the tracers it uses are critical in developing and measuring the effectiveness of drugs, diagnosing diseases, and guiding treatment decisions, which can drive demand, regulatory scrutiny, and revenue for related healthcare companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• New 48-week KINECT^® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnormal Involuntary Movement Scale total score); INGREZZA is the only vesicular monoamine transporter 2 (VMAT2) inhibitor to demonstrate clinical remission in clinical trials
• A separate claims analysis indicates high prevalence of hepatic risk factors among patients with tardive dyskinesia; INGREZZA is the only VMAT2 inhibitor with approved dosing in hepatic impairment
• Together, these data add to a growing body of evidence supporting the potential of INGREZZA to provide clinically meaningful therapeutic benefits to a wide range of patients with tardive dyskinesia

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new post-hoc data from the KINECT^® 4 clinical trial demonstrating that adults with tardive dyskinesia (TD) treated with INGREZZA^® (valbenazine) capsules experienced clinically meaningful and robust improvements in involuntary movement severity, including those who did not meet the stringent symptomatic remission threshold. These results, together with findings from a large retrospective Medicare claims analysis evaluating hepatic risk factors among patients newly diagnosed with TD, were presented at the 2026 Psych Congress Elevate in Las Vegas.

Previously presented data from the 48-week KINECT 4 study showed that 59% (61/103) of patients treated with once-daily INGREZZA achieved the stringent threshold for TD symptomatic remission, defined as an Abnormal Involuntary Movement Scale (AIMS) item score of 0 ("none") or 1 ("minimal movements") in each of the seven body regions. Symptomatic remission was achieved across TD movement severity subgroups, including 63% (38/60) of patients with moderate TD and 54% (23/43) of patients with severe TD. A new post-hoc analysis further demonstrated that clinically meaningful improvements were observed even among patients who did not meet the more stringent symptomatic remission threshold. Among the 41% of patients (42/103) who did not meet the symptomatic remission threshold at Week 48, 86% (36/42) achieved ≥30% total AIMS score reduction (characterized by the authors as clinically meaningful), and 67% (28/42) achieved ≥50% reduction.

"Treatment goals for tardive dyskinesia include achieving both meaningful reductions in movement severity and, when possible, reaching symptomatic remission, a stringent threshold characterized by absent or minimal involuntary movements across all seven body regions," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "This new analysis demonstrates that approximately 94% of patients treated with INGREZZA for 48 weeks either achieved symptomatic remission or experienced clinically meaningful reductions in their tardive dyskinesia movements. Notably, the benefits of treatment extended beyond patients who reached the stringent remission threshold, reinforcing the broad clinical impact of INGREZZA."

Claims Analysis Underscores Importance of Evaluating Hepatic Risk Factors in TD Treatment Decisions

A separate retrospective Medicare claims analysis of more than 176,000 patients newly diagnosed with TD found that 90% of patients had at least one hepatic risk factor and 44% had three or more. Selected hepatic risk factors included metabolic conditions, such as type 2 diabetes, hypertension, hyperlipidemia and obesity, in addition to substance use-related factors, such as alcohol or drug abuse, are associated with chronic liver disease or hepatic impairment. These findings highlight the importance of evaluating hepatic risk factors when making individualized treatment decisions for TD, as chronic liver disease may progress without noticeable symptoms, and hepatic impairment may go unrecognized, particularly in mild cases. INGREZZA is the only vesicular monoamine transporter 2 inhibitor with approved dosing for patients with TD and coexisting hepatic impairment.

Additional presentations at the 2026 Psych Congress Elevate included: 

• Evidence-Based Recommendations for Treating Tardive Dyskinesia with a Vesicular Monoamine Transporter 2 Inhibitor
• Clinically Meaningful Improvements and Symptomatic Remission with Once-Daily Valbenazine in Adults with Tardive Dyskinesia
• Patients Taking Once-Daily Valbenazine Report Improved Quality of Life/Functionality and Experience Remission of Tardive Dyskinesia Symptoms with Once-Daily Valbenazine: Findings From KINECT-PRO
• Once‑Daily Valbenazine Demonstrates Greater and More Predictable Exposure Than Deutetrabenazine Extended‑Release: Results from a Positron Emission Tomography Study in Healthy Male Adults
• Characterizing Hepatic Risk Factors Among Medicare Patients with Tardive Dyskinesia

About the KINECT 4 Phase 3 Study
KINECT 4 is a Phase 3, open-label study in which 163 participants with moderate to severe TD and underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder) received 48 weeks of open-label treatment with once-daily INGREZZA (40 mg or 80 mg capsules) followed by a four-week washout. Dosing was initiated at 40 mg/day in all participants, with escalation to 80 mg/day at Week 4 based on effectiveness and tolerability. Dose reduction to 40 mg was allowed in participants who could not tolerate the 80 mg dose. Patients were discontinued if the new dose was not tolerated.

Participants experienced TD improvements during long-term treatment as demonstrated by mean change from baseline to Week 48 in AIMS total score (sum of items 1-7, evaluated by site raters) with INGREZZA 40 mg/day (-10.2) or 80 mg/day (-11.0). Consistent with previous studies, INGREZZA was generally well tolerated. After Week 4, treatment-emergent adverse events that occurred in ≥5% of all participants (combined dose groups) were urinary tract infection (8.5%) and headache (5.2%). Changes from baseline in psychiatric stability, vital signs, electrocardiogram parameters and laboratory test values were generally small and not clinically significant.

About Tardive Dyskinesia 
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrolled, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be mild to severe and are often persistent and irreversible. TD is estimated to affect at least 800,000 adults in the U.S.

About INGREZZA^® (valbenazine) Capsules and INGREZZA^® SPRINKLE (valbenazine) Capsules 
INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD). Only INGREZZA offers a therapeutic dose from day one with no required titration. 

INGREZZA, developed by Neurocrine Biosciences, selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. While the specific way INGREZZA works to treat TD and HD chorea is not fully understood, INGREZZA is unique in that it selectively and specifically targets VMAT2 to inhibit the release of dopamine, a chemical in the brain that helps control movement. INGREZZA is believed to reduce extra dopamine signaling, which may lead to fewer uncontrollable movements. 

INGREZZA is studied across the widest range of patients. It is always one capsule, once daily and can be taken together with most stable mental health regimens such as antipsychotics or antidepressants. Only INGREZZA offers the benefit of a sprinkle formulation, INGREZZA SPRINKLE, for those who experience dysphagia, have difficulty swallowing or prefer not to swallow a pill. INGREZZA and INGREZZA SPRINKLE dosages approved for use are 40 mg, 60 mg and 80 mg capsules. 

Important Information 

Approved Uses 
INGREZZA^®(valbenazine) capsules or INGREZZA^® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with: 

• movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia). 
• involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. 

It is not known if INGREZZA or INGREZZA SPRINKLE is safe and effective in children. 

IMPORTANT SAFETY INFORMATION 

INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself. 

Do not take INGREZZA or INGREZZA SPRINKLE if you:

• are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE.

INGREZZA or INGREZZA SPRINKLE can cause serious side effects, including:

• Allergic reactions. Allergic reactions, including an allergic reaction that causes sudden swelling called angioedema, can happen after taking the first dose or after many doses of INGREZZA or INGREZZA SPRINKLE. Signs and symptoms of allergic reactions and angioedema include: trouble breathing or shortness of breath, swelling of your face, lips, eyelids, tongue, or throat, or other areas of your skin, trouble with swallowing, or rash, including raised, itchy red areas on your skin (hives). Swelling in the throat can be life-threatening and can lead to death. Stop taking INGREZZA or INGREZZA SPRINKLE and go to the nearest emergency room right away if you develop these signs and symptoms of allergic reactions and angioedema.
• Sleepiness and tiredness that could cause slow reaction times (somnolence and sedation). Do not drive a car or operate dangerous machinery until you know how INGREZZA or INGREZZA SPRINKLE affects you. Drinking alcohol and taking other medicines may also cause sleepiness during treatment with INGREZZA or INGREZZA SPRINKLE.
• Heart rhythm problems (QT prolongation). INGREZZA or INGREZZA SPRINKLE may cause a heart rhythm problem known as QT prolongation. You have a higher chance of getting QT prolongation if you also take certain other medicines during treatment with INGREZZA or INGREZZA SPRINKLE. Tell your healthcare provider right away if you develop any signs or symptoms of QT prolongation, including: fast, slow, or irregular heartbeat (heart palpitations), shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint.
• Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms and they do not have another obvious cause: high fever, stiff muscles, problems thinking, irregular pulse or blood pressure, increased sweating, or very fast or uneven heartbeat.
• Parkinson-like symptoms. Symptoms include: body stiffness, drooling, trouble moving or walking, trouble keeping your balance, shaking (tremors), or falls. 

Before taking INGREZZA or INGREZZA SPRINKLE, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. 

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure you tell all of your healthcare providers that you are taking INGREZZA or INGREZZA SPRINKLE. Taking INGREZZA or INGREZZA SPRINKLE with certain other medicines may cause serious side effects. Especially tell your healthcare provider if you: take digoxin or take or have taken a monoamine oxidase inhibitor (MAOI) medicine. You should not take INGREZZA or INGREZZA SPRINKLE if you are taking, or have stopped taking, a MAOI within the last 14 days. 

The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with tardive dyskinesia are sleepiness and tiredness. 

The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with chorea associated with Huntington's disease include sleepiness and tiredness, raised itchy red areas on your skin (hives), rash, and trouble getting to sleep or staying asleep. 

These are not all of the possible side effects of INGREZZA or INGREZZA SPRINKLE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. 

Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules. 

Please see full Prescribing Information, including Boxed Warning, and Medication Guide. 

About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie) 

The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, INGREZZA and KINECT are registered trademarks of Neurocrine Biosciences, Inc. KINECT-PRO is a trademark of Neurocrine Biosciences, Inc.

Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from INGREZZA, the interpretation and potential relevance of the data described in this press release, including statements regarding clinically meaningful reductions in involuntary movement severity, symptomatic remission, and hepatic risk factors among patients with tardive dyskinesia, and the value INGREZZA may bring to patients. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of INGREZZA; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of INGREZZA; whether INGREZZA receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA; risks associated with the Company's dependence on third parties for development and manufacturing activities related to INGREZZA, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for INGREZZA or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding INGREZZA; risks that post-approval INGREZZA commitments or requirements may be delayed; risks that INGREZZA may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. 

© 2026 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-VBZ-US-0105   06/2026

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-clinically-meaningful-response-data-on-treatment-of-tardive-dyskinesia-reinforcing-the-efficacy-of-ingrezza-valbenazine-capsules-across-a-broad-range-of-patients-302794193.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

What new INGREZZA (NBIX) efficacy data were presented on June 8, 2026?

Neurocrine Biosciences reported that about 94% of INGREZZA-treated tardive dyskinesia patients achieved symptomatic remission or a clinically meaningful AIMS reduction after 48 weeks. According to Neurocrine Biosciences, this comes from a post-hoc analysis of the long-term KINECT 4 clinical trial.

What does the 48-week KINECT 4 study show about INGREZZA response rates for NBIX?

The 48-week KINECT 4 study found 59% of adults with tardive dyskinesia achieved symptomatic remission on once-daily INGREZZA. According to Neurocrine Biosciences, among remaining patients, 86% reached ≥30% and 67% reached ≥50% reductions in total AIMS scores.

How effective is INGREZZA (NBIX) in moderate and severe tardive dyskinesia?

INGREZZA achieved symptomatic remission in 63% of patients with moderate tardive dyskinesia and 54% with severe disease. According to Neurocrine Biosciences, remission was defined as AIMS item scores of 0 or 1 across all seven body regions after 48 weeks.

What did the Medicare claims analysis reveal about hepatic risk factors in TD patients relevant to NBIX?

A retrospective Medicare claims analysis of over 176,000 newly diagnosed tardive dyskinesia patients showed 90% had at least one hepatic risk factor and 44% had three or more. According to Neurocrine Biosciences, these risks included metabolic conditions and substance use-related factors.

Why are hepatic risk factors important when selecting INGREZZA (NBIX) for tardive dyskinesia treatment?

Hepatic risk factors matter because chronic liver disease can progress without symptoms and hepatic impairment may be missed. According to Neurocrine Biosciences, INGREZZA is the only VMAT2 inhibitor with approved dosing for tardive dyskinesia patients who also have hepatic impairment.

How is a clinically meaningful response to INGREZZA defined in the KINECT 4 analysis for NBIX?

Clinically meaningful response was defined as a ≥30% reduction from baseline in total AIMS score among tardive dyskinesia patients. According to Neurocrine Biosciences, many patients not reaching full symptomatic remission still met this ≥30% threshold and some achieved ≥50% reductions.

What additional INGREZZA-related presentations involving NBIX were given at the 2026 Psych Congress Elevate?

Neurocrine Biosciences presented evidence-based treatment recommendations, KINECT-PRO quality-of-life results, and PET data comparing valbenazine exposure with deutetrabenazine. According to Neurocrine Biosciences, another presentation characterized hepatic risk factors among Medicare patients with tardive dyskinesia.